21 January 2026 Immuthera appoints Dr. Antionette Moran, Dr. Jason Gaglia, and Dr. Jeffrey Cohen to the Scientific Advisory Board (SAB) Read more
12 January 2026 Immuthera announces global exclusive license from City of Hope for First-in-Class CD6/CTLA-4 CAR-Treg platform for autoimmune and inflammatory diseases Read more
07 November 2025 Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies Read more
31 July 2025 Immuthera and Parent Company PolTREG Secures Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial Read more
13 June 2025 PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy Read more